Inhibition kinetics of monoclonal antibodies against cytochromes P450

Drug Metabolism and Disposition

Volumn 30, Issue 6, 2002, Pages 701-708

  Mei, Qin ^a   Tang, Cuyue ^a   Lin, Yuh ^a   Rushmore, Thomas H ^a   Shou, Magang ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; BUFURALOL; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; MONOCLONAL ANTIBODY; TESTOSTERONE;

ARTICLE; DEMETHYLATION; DISSOCIATION CONSTANT; DRUG METABOLISM; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYBRIDOMA; HYDROXYLATION; KINETICS; MASS SPECTROMETRY; MODEL; PREDICTION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

AFLATOXINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; ETHANOLAMINES; HUMANS; HYBRIDOMAS; HYDROXYLATION; IMMUNOGLOBULIN G; ISOENZYMES; KINETICS; MACACA MULATTA; MICE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; RATS; SPECIES SPECIFICITY; TESTOSTERONE;

EID: 0036260006     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.6.701     Document Type: Article

References (38)

1. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
2. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
3. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination
4. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
5. Polymorphic cytochrome P450 and drugs used in psychiatry
6. Optimization of cytochrome P450 2D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allel frequency data
7. Cytochrome P450 and monoclonal antibodies
8. Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4
9. Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: A new avenue for drug discovery
10. A monoclonal antibody inhibitory to human P450 2D6: A paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism
11. The molecular biology of cytochrome P450s
12. The CYP2D subfamily
13. Basic pharmacokinetic principles and their application to psychotropic drugs
14. Metabolic activation of carcinogens
15. Selective inhibitors of cytochromes P450
16. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
17. Interethnic variation of drug metabolism
18. Inhibitory monoclonal antibodies to human cytochrome P450 2D6
19. "It's the genes, stupid": Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism
20. Role of pharmacokinetics and metabolism in drug discovery and development
21. The role of CYP2C19 9n the metabolism Of (±) bufuralol, the prototypic substrate of CYP2D6
22. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism
23. Pharmacogenetics: The slow, the rapid, and the ultrarapid
24. Antidepressants and drug-metabolizing enzymes-expert group report
25. P450 superfamily: Update on new sequences. Gene mapping, accession numbers and nomenclature
26. Preparation and characterization of monoclonal antibodies to pregnenolone 16α-carbonitrile inducible rat liver cytochrome P450
27. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates
28. Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: The need for quantitative databases
29. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450
30. The potential role of the cytochrome P450 2D6 pharmacogenetic polymorphism in drug abuse
31. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
32. Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism
33. Sigmoidal kinetic model for two cooperative substrate-binding sites in a cytochrome P450 3A4 active site: An example of the metabolism of diazepam and its derivatives
34. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California
35. Inhibitory anti-peptide antibody against human CYP3A4
36. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6
37. The human hepatic cytochromes P450 involved in drug metabolism
38. Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism